NEHREN, Germany, March 22, 2019 /PRNewswire/ -- In time for the
World Tuberculosis (TB) Day 2019 on Sunday, March 24th
(www.who.int/campaigns/world-tb-day/world-tb-day-2019), Bruker
today announced the launch of an important further innovation in
the field of tuberculosis diagnostics.
According to the World Health Organization (WHO), TB is among
the most dangerous infectious diseases worldwide, ranking alongside
HIV/AIDS (https://www.who.int/tb/en/) as a cause for death. One of
the targets of the United Nations' Sustainable Development Goals
for 2030 is to end the tuberculosis epidemic
(https://www.un.org/pga/73/event/fight-to-end-tuberculosis/), which
demands a global effort to tackle the rise of multi-drug-resistant
TB (MDR-TB) and extensively-drug-resistant TB (XDR-TB). MDR-TB is
resistant to the first-line drugs isoniazid (INH) and rifampicin
(RIF), and XDR-TB in addition has developed resistance to
fluoroquinolone and the injectable compounds used. The rapid
diagnosis and appropriate treatment of both MDR-TB and XDR-TB is
therefore essential to prevent significant morbidity, mortality and
further transmission of the disease.
In recent years an increased spectrum of anti-mycobacterial
resistance, and therefore an increased number of MDR and XDR cases
has been observed. Conventional antibiotic susceptibility testing
(AST) methods for TB can take an extremely long time to yield
results, require significant laboratory infrastructure and
training, and are potentially biohazardous. As a result, there is
still under-diagnosis and a gap between acute TB cases and TB
notifications.
The new PCR-based FluoroType MTBDR 2.0 assay
identifies tuberculosis pathogens, as well as several important
antibiotic resistance characteristics in only three hours. The
novel assay detects TB pathogens directly from patient samples,
without the need for any culture. In addition, it can be used to
detect MDR-TB, i.e. resistance against rifampicin and isoniazid,
the two most important first line TB drugs. This novel TB test
relies on the innovative Bruker-Hain Liquid Array technology
to analyze a multitude of mutations in the associated TB resistance
genes.
The new FluoroCycler XT is a novel,
high-performance thermal cycler and optical reader that enables the
Liquid Array assay technology. The FluoroType MTBDR
2.0 assay can detect more than 60 mutations in the TB
genes, leading up to 522 resistance patterns with relevant
information to guide therapy. This level of genetic specificity
normally can only be achieved with sequencing.
Dr. Jaime Esteban from the Depto.
Microbiología Clínica at the Universidad Autónoma de Madrid stated: "We will implement the new
high-resolution FluoroType MTBDR 2.0 test together
with the newly developed, high-performance optical
FluoroCycler XT to improve our ability to diagnose
acute TB with greater specificity and as quickly as possible."
The FluoroCycler XT PCR system and the
FluoroType MTBDR 2.0 assay were CE-IVD registered in
January 2019. With their combined
launch, the fight against TB has a new tool for advanced testing to
provide superior diagnostic information.
David Hain, Managing Director of
Bruker-Hain Diagnostics, said: "With introduction of the
FluoroType MTBDR 2.0 Liquid
Array assay for in-depth tuberculosis testing on our
innovative FluoroCycler XT platform, Bruker supports
the multinational healthcare objective to improve diagnosis for
improved personalized therapy of acute tuberculosis."
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker's high-performance scientific instruments and
high-value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular research, in applied and pharma applications, in
microscopy and nanoanalysis, and in industrial applications, as
well as in cell biology, preclinical imaging, clinical phenomics
and proteomics research and clinical microbiology. For more
information, please visit: www.bruker.com.
About Bruker-Hain Diagnostics
Bruker-Hain Diagnostics was formed after the recent acquisition
of a majority share of the Hain Lifescience GmbH as a Business Unit
for Molecular Diagnostics (MDx) products in Bruker´s Microbiology
& Diagnostics business. Hain Lifescience GmbH is the legal
manufacturer of the FluoroCycler XT and the
MTBDR 2.0 assay. For more information, please visit,
www.hain-lifescience.de.
Investor
Contact:
Miroslava
Minkova
Director, Investor Relations & Corporate Development
Bruker
Corporation
T: +1 (978) 663–3660, ext.
1479
E: miroslava.minkova@bruker.com
Contact for Media and Customers:
David Hain
Bruker-Hain Diagnostics
Managing Director
Hain Lifescience GmbH
Tel: +49-171-331-4645
E: David.Hain@bruker.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bruker-announces-improved-assay-for-tuberculosis-diagnostics-in-novel-liquid-array-format-for-improved-multiplexing-300816896.html
SOURCE Bruker Corporation